A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

被引：4

作者：

Daver, Naval G. ^{[1
]}

Kremyanskaya, Marina ^{[2
]}

O'Connell, Casey ^{[3
]}

Dao, Kim-Hien ^{[4
]}

Oh, Stephen T. ^{[5
]}

Gerds, Aaron T. ^{[6
]}

Verstovsek, Srdan ^{[1
]}

Erickson-Viitanen, Sue ^{[7
]}

Zhou, Feng ^{[7
]}

Assad, Albert ^{[7
]}

Yacoub, Abdulraheem ^{[8
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Mt Sinai Hlth Syst, New York, NY USA

[3] Univ Southern Calif, Los Angeles, CA USA

[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[5] Washington Univ, Sch Med, St Louis, MO USA

[6] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[7] Incyte Corp, Wilmington, DE USA

[8] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-111338

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

353

引用

页数：3

共 50 条

[1] A Phase 2 Study of the Safety and Efficacy of INCB050465 in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)
Daver, Naval
Dao, Kim-Hien
Assad, Albert
Verstovsek, Srdan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S351 - S351
[2] Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: a phase 2 study in patients with myelofibrosis
Yacoub, Abdulraheem
Wang, Eunice
Rampal, Raajit
Borate, Uma
Kremyanskaya, Marina
Ali, Haris
Hobbs, Gabriela
O'Connell, Casey
Assad, Albert
Erickson-Viitanen, Sue
Zhou, Feng
Burn, Timothy
Daver, Naval
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 9 - 9
[3] Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis.
Yacoub, Abdulraheem
Wang, Eunice S.
Rampal, Raajit K.
Borate, Uma
Kremyanskaya, Marina
Ali, Haris
Hobbs, Gabriela S.
O'Connell, Casey
Assad, Albert
Erickson-Viitanen, Sue
Zhou, Feng
Burn, Timothy C.
Daver, Naval G.
CANCER RESEARCH, 2021, 81 (13)
[4] Preclinical studies on potential therapeutic combination partners for the potent and selective PI3Kδ inhibitor INCB050465 in DLBCL
Stubbs, Matthew C.
Collins, Robert
Hall, Leslie
Volgina, Alla
Koblish, Holly
Lee, Sang Hyun
Burn, Timothy
Liu, Phillip C.
Lu, Jin
Yue, Eddy
Li, Yun-Long
Combs, Andrew P.
Yao, Wenqing
Hollis, Gregory
Huber, Reid
Ruggeri, Bruce
Scherle, Peggy
CANCER RESEARCH, 2017, 77
[5] Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)
Yacoub, Abdulraheem
Borate, Uma
Rampal, Raajit
Ali, Haris
Wang, Eunice S.
Gerds, Aaron T.
Hobbs, Gabriela
Kremyanskaya, Marina
Winton, Elliott
O'Connell, Casey
Goel, Swati
Oh, Stephen
Schiller, Gary J.
Assad, Albert
Erickson-Viitanen, Sue
Zhou, Feng
Daver, Naval
BLOOD, 2021, 138
[6] An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies
Phillips, Tycel
Ramchandren, Rod
Wertheim, Michael S.
Gutierrez, Martin E.
Edenfield, William J.
Dawkins, Fitzroy
DeMarini, Doug J.
Zhou, Li
Yeleswaram, Swamy
Newton, Robert C.
Chen, Xuejun
Forero-Torres, Andres
BLOOD, 2016, 128 (22)
[7] Results From a Phase 1/2 Study of INCB050465, a Potent and Highly Selective PI3K delta Inhibitor, in Patients With Relapsed or Refractory B-Cell Malignancies
Martin, Peter
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 9 - 10
[8] INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ)
Yue, Eddy W.
Li, Yun-Long
Douty, Brent
He, Chunhong
Mei, Song
Wayland, Brian
Maduskuie, Thomas
Falahatpisheh, Nikoo
Sparks, Richard B.
Polam, Padmaja
Zhu, Wenyu
Glenn, Joseph
Feng, Hao
Zhang, Ke
Li, Yanlong
He, Xin
Katiyar, Kamna
Covington, Maryanne
Feldman, Patricia
Shin, Niu
Wang, Kathy He
Diamond, Sharon
Li, Yu
Koblish, Holly K.
Hall, Leslie
Scherle, Peggy
Yeleswaram, Swamy
Xue, Chu-Biao
Metcalf, Brian
Combs, Andrew P.
Yao, Wenqing
ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (11): : 1554 - +
[9] Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)
Forero-Torres, Andres
Ramchandren, Rod
Yacoub, Abdulraheem
Wertheim, Michael S.
Edenfield, William J.
Caimi, Paolo
Gutierrez, Martin
Akard, Luke
Escobar, Carolina
Call, Justin
Persky, Daniel
Iyer, Swami P.
DeMarini, Douglas J.
Zhou, Li
Yeleswaram, Swamy
Phillips, Tycel J.
BLOOD, 2017, 130
[10] INCB050465, a novel PI3Kδ inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL
Shin, Niu
Koblish, Holly
Covington, Maryanne
Li, Yanlong
Wang, Kathy
Wang, Qian
Feldman, Patricia
Hall, Leslie
O'Connor, Sybil
He, Xin
Katiyar, Kamna
Li, Yu
Yue, Eddy W.
Maduskuie, Thomas P.
Douty, Brent
Mei, Song
Li, Yun-Long
Xue, Chu-Biao
Combs, Andrew
Yao, Wenqing
Diamond-Fosbenner, Sharon
Yeleswaram, Swamy
Newton, Robert
Vaddi, Kris
Huber, Reid
Scherle, Peggy
CANCER RESEARCH, 2015, 75

← 1 2 3 4 5 →